XOMA Royalty (XOMA) Projected to Post Quarterly Earnings on Monday

XOMA Royalty (NASDAQ:XOMA) is expected to release its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect XOMA Royalty to post earnings of ($0.04) per share and revenue of $11.13 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 18, 2026 at 8:00 AM ET.

XOMA Royalty Stock Down 1.8%

NASDAQ XOMA opened at $26.38 on Friday. The business has a fifty day moving average price of $26.12 and a two-hundred day moving average price of $30.64. The company has a debt-to-equity ratio of 1.07, a current ratio of 3.91 and a quick ratio of 3.91. XOMA Royalty has a fifty-two week low of $18.35 and a fifty-two week high of $39.92. The stock has a market capitalization of $326.58 million, a PE ratio of 35.65 and a beta of 0.86.

Analyst Ratings Changes

XOMA has been the subject of a number of research analyst reports. Stifel Nicolaus set a $50.00 price target on XOMA Royalty in a report on Friday, December 12th. Wall Street Zen cut XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. UBS Group set a $76.00 target price on shares of XOMA Royalty in a report on Tuesday, December 9th. TD Cowen upgraded shares of XOMA Royalty to a “hold” rating in a research note on Friday, February 13th. Finally, Benchmark reaffirmed a “buy” rating on shares of XOMA Royalty in a report on Friday, December 12th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, XOMA Royalty currently has a consensus rating of “Hold” and an average target price of $61.60.

Institutional Trading of XOMA Royalty

A number of institutional investors and hedge funds have recently bought and sold shares of XOMA. Opaleye Management Inc. raised its position in XOMA Royalty by 14.7% during the 4th quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock worth $7,780,000 after purchasing an additional 37,503 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of XOMA Royalty in the 4th quarter valued at about $237,000. Panagora Asset Management Inc. increased its stake in shares of XOMA Royalty by 24.2% in the fourth quarter. Panagora Asset Management Inc. now owns 21,229 shares of the biotechnology company’s stock valued at $564,000 after buying an additional 4,135 shares during the period. Barclays PLC increased its stake in shares of XOMA Royalty by 12.1% in the fourth quarter. Barclays PLC now owns 14,822 shares of the biotechnology company’s stock valued at $394,000 after buying an additional 1,598 shares during the period. Finally, State Street Corp raised its position in shares of XOMA Royalty by 4.7% during the fourth quarter. State Street Corp now owns 174,908 shares of the biotechnology company’s stock worth $4,651,000 after acquiring an additional 7,873 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.